4YB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetMinimal financial leverage reduces refinancing and interest-rate exposure, while substantial equity and assets provide resources to fund clinical development. This financial foundation gives Immunovant greater flexibility to sustain its pipeline and absorb setbacks over the next several quarters.
Broad Clinical PipelineA broad sequence of clinical readouts, regulatory milestones and potential launches creates several paths toward future product revenue rather than dependence on one event. This pipeline cadence can support development continuity and improve the company’s longer-term commercial optionality.
Promising Phase II EfficacyMeaningful Phase II efficacy in cutaneous sarcoidosis provides clinical support for pivotal development and commercialization planning. If replicated in registrational studies, the signal could help establish differentiated treatment value and improve the prospects for eventual market adoption.
Bears Say
Pre-Revenue And Widening LossesThe absence of commercial revenue leaves Immunovant dependent on financing, settlements or future approvals while its losses continue to widen. This weak earnings base reduces financial visibility and means the company must reach successful commercialization before operating results can become self-sustaining.
Heavy Cash BurnLarge recurring cash outflows consume resources before products generate revenue and can make future capital allocation more constrained. Although liquidity is substantial, continued burn increases dependence on successful clinical execution and eventual launches to preserve long-term financial flexibility.
Clinical And Trial Execution RiskVariable placebo responses, uncertain translation between indications and geographic differences can weaken trial power or complicate endpoint interpretation. These risks may delay regulatory progress or require additional evidence, making the pipeline’s value dependent on consistent results beyond Phase II.
Immunovant News
4YB FAQ
What was Immunovant’s price range in the past 12 months?
Currently, no data Available
What is Immunovant’s market cap?
Immunovant’s market cap is €5.43B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Oct 30, 2026 which is in 16 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Aug 06, 2026. The company reported -€0.669 earnings per share for the quarter, missing the consensus estimate of -€0.561 by -€0.108.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.66.
How many shares outstanding does Immunovant have?
Currently, no data Available
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -€0.669 in its last earnings report, missing expectations of -€0.561. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in DE:4YB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€43.92 (― Upside)
€43.92 (― Upside)
Blogger Sentiment
Bullish
DE:4YB Sentiment 71%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth €547.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.47%
12-Months-Change
Fundamentals
Return on Equity
-69.59%
Trailing 12-Months
Asset Growth
28.88%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunovant
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
4YB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial near-term and medium-term upside: a large multipart settlement that materially increases liquidity, an active and well-funded pipeline with multiple imminent readouts and a potential approval/launch for brexpiprazole in dermatomyositis, successful enrollments in registrational studies, and ongoing shareholder capital returns. These positives were balanced against recognized clinical and operational risks—placebo variability, translation risk for PH-ILD, JAK-class safety perceptions, geographic variability in trials, and continued high R&D and G&A spend. On balance, management presents confident execution and a strong catalyst calendar that outweigh the disclosed risks.View all DE:4YB earnings summaries4YB Stock 12 Month Forecast
Average Price Target
―TG Therapeutics
―
Viridian Therapeutics
―
Aurinia Pharmaceuticals
―
Protagonist Therapeutics
―
Kymera Therapeutics
―